Search results
Showing 76 to 90 of 182 results for pembrolizumab
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]
Awaiting development Reference number: GID-TA11073 Expected publication date: TBC
Awaiting development Reference number: GID-TA11469 Expected publication date: TBC
Awaiting development Reference number: GID-TA11931 Expected publication date: TBC
Evidence-based recommendations on bevacizumab (Avastin [originator] and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.
Awaiting development Reference number: GID-TA11724 Expected publication date: TBC
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Awaiting development Reference number: GID-TA11300 Expected publication date: TBC
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued Reference number: GID-TA10244
Awaiting development Reference number: GID-TA11202 Expected publication date: TBC
Pembrolizumab for previously treated multiple myeloma (ID1139)
Discontinued Reference number: GID-TA10193
Awaiting development Reference number: GID-TA11751 Expected publication date: TBC
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued Reference number: GID-TA10380
Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]
Discontinued Reference number: GID-TA10330
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued Reference number: GID-TA10418